Navigation Links
Ardea Biosciences Provides Additional Results From a Phase 2b Study of Lesinurad in Combination With Allopurinol at the Annual European Congress of Rheumatology
Date:5/25/2011

f gout patients are considered to be under-excretors of uric acid, and recent studies have shown that defects in renal transporters have been genetically linked to gout.  Consequently, increasing renal excretion of uric acid by moderating URAT1 transporter activity may provide the most physiologically appropriate treatment for gout.  In addition, because increasing the excretion of serum uric acid is additive to the effects of drugs that decrease the production of uric acid, such as allopurinol and febuxostat, lesinurad in combination with such drugs has the potential to treat the significant portion of the gout population that is not adequately treated with existing therapies.

Lesinurad has been evaluated as a single agent and in combination with the approved xanthine oxidase inhibitors, allopurinol and febuxostat.  Over 500 people have received lesinurad in Phase 1 and 2 clinical trials.

About Ardea Biosciences, Inc.

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases. Lesinurad, our lead product candidate for the treatment of hyperuricemia and gout, is a once-daily, oral inhibitor of the URAT1 transporter.  We have completed Phase 2b clinical studies of lesinurad and continue to advance the drug in longer term extensions in preparation for Phase 3 development.  Our next-generation URAT1 inhibitor program is currently in preclinical development. BAY 86-9766 (RDEA119), is a potent and specific inhibitor of mitogen-activated ERK kinase (MEK) for the treatment of cancer being developed under a global license agreement with Bayer HealthCare AG. BAY 86-9766 is currently in a Phase 2 study in patients with hepatocellular carcinoma in combination with sorafenib (Nexavar®; Bayer, Onyx Pharmaceuticals) and a Phase 1/Phase 2 study in patients with advanced pancreatic cancer in combinatio
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
11. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... und LONDON , July ... , Ziel der Zusammenarbeit sind Entwicklung und Kommerzialisierung ... Plasmaproben zur Steuerung von Therapien mit IRESSA bei ... Neuer Bluttest basiert auf QIAGENs von der ... Rotor-Gene Q, einer Automationsplattform der QIAsymphony-Produktfamilie, laufen  ...
(Date:7/28/2014)... , Germany and ... , Collaboration aims to create and ... to guide the use of IRESSA  for non-small cell ... build on QIAGEN,s FDA-approved  therascreen   EGFR test and is ... of automated instruments  Project enabled by AstraZeneca ...
(Date:7/28/2014)... , July 28, 2014 CTI BioPharma ... it will report its second quarter 2014 financial results ... the U.S. financial markets. Following the announcement, members of ... to discuss the results and provide a general corporate ... to the event can be obtained as follows: ...
Breaking Medicine Technology:QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 3QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 4QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 5QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 6QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 7QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 3QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 4QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 5QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 6CTI BioPharma to Report Second Quarter 2014 Financial Results on August 4, 2014 2
... Receiving the herpes zoster vaccine was associated with a ... Kaiser Permanente study of 300,000 people that appears in the ... Association . This retrospective study observed the outcomes ... large, diverse population of men and women ages 60 years ...
... 11, 2011 Celleration, Inc., a privately held medical ... products, today announced the closing of an $8 million ... Company,s existing institutional investors participated in this round in ... a new investor. "The addition of ...
Cached Medicine Technology:Shingles Vaccine Associated With 55 Percent Reduced Risk of Disease 2Shingles Vaccine Associated With 55 Percent Reduced Risk of Disease 3Shingles Vaccine Associated With 55 Percent Reduced Risk of Disease 4
(Date:7/28/2014)... (PRWEB) July 28, 2014 To commemorate ... Editorial Board of Living with a Disability magazine ... disabling digestive disorders that include hepatitis, gastrointestinal hemorrhage, inflammatory ... , The important new article highlights that, in the ... afflicted with hepatitis and other disabling conditions related to ...
(Date:7/28/2014)... July 28, 2014 According to the Heartburn ... a comprehensive guide that will help people get rid of ... all the necessary information about heartburn and acid reflux. In ... about heartburn , and risk factors for reflux disease. ... help people get rid of symptoms of reflux disease naturally ...
(Date:7/28/2014)... According to the Drama Method Pdf review ... that helps women easily get the attention of the men ... in its review that this book can teach ladies how ... The book also instructs them how to conquer a man, ... Drama Method review that this book is divided into 30 ...
(Date:7/28/2014)... 2014 Building a sense of neighborhood ... Where personal outdoor space is not possible, building ... fun and exercise outside is important. That’s why ... quality commercial playground equipment from APCPLAY. , Old Buckingham ... Virginia. It is an historic tourist location of one ...
(Date:7/28/2014)... Mitul R. Patel, DDS and concerned leading Dentists ... Experts Benefit Dinner May 30, in St. Petersburg, FL. ... raise funds for the Improving Youth Literacy Campaign in ... Programs across America. The funds raised are providing hundreds ... books to directly tackle illiteracy and help to break ...
Breaking Medicine News(10 mins):Health News:Living with a Disability Magazine Marks World Hepatitis Day on July 28 with New Article on Disabling Digestive Disorders 2Health News:Living with a Disability Magazine Marks World Hepatitis Day on July 28 with New Article on Disabling Digestive Disorders 3Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 2Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 3Health News:The Drama Method Pdf Review Exposes Aaron Fox's Relationship Guide – Vkool.com 2Health News:The Drama Method Pdf Review Exposes Aaron Fox's Relationship Guide – Vkool.com 3Health News:Playground Creates Outdoor Fun for Community at Old Buckingham Station at Midlothian Village (VA) with APCPLAY© 2Health News:Mitul R. Patel, DDS Successfully Attacks a Major Source of Economic Destruction in the Battle Against Illiteracy and Poverty 2Health News:Mitul R. Patel, DDS Successfully Attacks a Major Source of Economic Destruction in the Battle Against Illiteracy and Poverty 3
... depression, study suggests , , WEDNESDAY, Aug. 29 (HealthDay News) -- ... be as simple as seeing which arm she uses to ... mothers who cradle their baby on their right side may ... mothers feel some levels of stress during the first weeks ...
... a 58-year-old business owner from Waxahachie, Texas, was fortunate. ... but a side effect of his successful surgery was ... cancer, I started experiencing incontinence, said Mr. Yarborough, who ... better than most, the condition, simply put, drove me ...
... anesthesia, faster recovery, less cost, study finds , , TUESDAY, Aug. ... may ease the pain of surgery -- both during and ... who received hypnosis before breast cancer surgery needed less anesthesia ... in the operating room and had reduced costs. , ...
... and therapies, researchers say , , TUESDAY, Aug. 28 (HealthDay ... of multiple sclerosis patients may help predict the severity ... reporting. , "This is a new way to ... of the patient,s lesions," said lead researcher Dr. Rohit ...
... ear, nose and throat specialists at Thomas Jefferson University ... apnea syndrome. , In the procedure, known as Genial ... lower jaw which attaches to the tongue is moved ... of the airway, increasing the airway space. It is ...
... Genes connected with higher functions are changed by continued ... -- Alcoholics with cirrhosis (scarring and dysfunction) of the ... according to new research. , Researchers examined gene expression ... alcoholics with cirrhosis and 14 alcoholics without cirrhosis. , ...
Cached Medicine News:Health News:Stressed-Out Moms Carry Babies on the Right 2Health News:New male sling procedure helps prostate cancer survivors who suffer from urinary incontinence 2Health News:Hypnosis Eases Pain of Breast Cancer Surgery 2Health News:Hypnosis Eases Pain of Breast Cancer Surgery 3Health News:Brain Lesions Predict MS Progression 2Health News:Brain Lesions Predict MS Progression 3Health News:Jefferson specialists studying innovative surgery for effectively treating sleep apnea 2Health News:Alcoholics With Cirrhosis Have More Brain Damage 2
Stryker Leibinger offers a variety of different Titanium Implant Systems and special instrument sets, which enable our customers to treat a wide range of indication...
Stryker Leibinger offers a variety of different Titanium Implant Systems and special instrument sets, which enable our customers to treat a wide range of indication...
Anatomical implants for the entire hand, in five sizes...
... a brief magnetic pulse to stimulate deep ... in Magnetic Nerve Stimulators. Based upon equipment ... in 1985. A powerful monophasic stimulator for ... best stimulator for Central Motor Conduction Studies, ...
Medicine Products: